SCHEMBL18081979

SCHEMBL18081979

Cn1cc2c(=O)cc[nH]c2nc1=O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 3/20 0.53
ADORA1 P30542 2/20 0.53
KDM4E B2RXH2 1/20 0.39
CCR8 P51685 1/20 0.38
DYRK1A Q13627 1/20 0.38
KMT2A Q03164 2/20 0.37
CCNT1 O60563 1/20 0.35
CCNA2 P20248 1/20 0.35
CDK2 P24941 1/20 0.35
CDK9 P50750 1/20 0.35
CCNA1 P78396 1/20 0.35
CDK5 Q00535 1/20 0.35
CDK5R1 Q15078 1/20 0.35
BRD4 O60885 2/20 0.35
TAF1 P21675 1/20 0.35
BRPF1 P55201 1/20 0.35
CREBBP Q92793 1/20 0.35
CECR2 Q9BXF3 1/20 0.35
BRD9 Q9H8M2 1/20 0.35
ALDH1A1 P00352 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18081928 0.83 ADORA2A (0.50) ADORA2AADORA1KDM4ECCR8DYRK1A
SCHEMBL13183286 0.80 BRD4 (0.42) ADORA2AADORA1KDM4EDYRK1AKMT2A
SCHEMBL18080573 0.79 ADORA2A (0.50) ADORA2AADORA1KDM4ECCR8DYRK1A
SCHEMBL16631753 0.79 ADORA2A (0.49) ADORA2AADORA1KDM4ECCR8DYRK1A
SCHEMBL811103 0.75 ADORA2A (0.47) ADORA2AADORA1KDM4ECCR8KMT2A
SCHEMBL18081791 0.74 ADORA2A (0.32) ADORA2AADORA1KMT2ABRD4
SCHEMBL16631610 0.72
SCHEMBL16631773 0.71 ADORA1 (0.51) ADORA2AADORA1KDM4EALDH1A1SMN1; SMN2
SCHEMBL18080575 0.70 ADORA2A (0.48) ADORA2AADORA1KDM4ECCR8DYRK1A
SCHEMBL16631757 0.70 ADORA2A (0.46) ADORA2AADORA1KDM4ECCR8DYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160264614-A1 POLYNUCLEOTIDE MOLECULES AND USES THEREOF MODERNA THERAPEUTICS, INC. (US) 2016-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160264614-A1 POLYNUCLEOTIDE MOLECULES AND USES THEREOF POLRMT, POLN, NSUN3 ADORA2A 619/4885ADORA1 1601/4885KDM4E 4689/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.